Telix Pharmaceuticals Ltd
ASX:TLX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.17
23.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd
PP&E Net
Telix Pharmaceuticals Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
PP&E Net
AU$30.5m
|
CAGR 3-Years
85%
|
CAGR 5-Years
167%
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
PP&E Net
AU$679.7k
|
CAGR 3-Years
30%
|
CAGR 5-Years
67%
|
CAGR 10-Years
2%
|
|
|
Mesoblast Ltd
ASX:MSB
|
PP&E Net
$3.8m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
PP&E Net
$9.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
17%
|
CAGR 10-Years
18%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
PP&E Net
AU$7.7m
|
CAGR 3-Years
44%
|
CAGR 5-Years
61%
|
CAGR 10-Years
53%
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
PP&E Net
AU$1.6m
|
CAGR 3-Years
2%
|
CAGR 5-Years
27%
|
CAGR 10-Years
17%
|
|
Telix Pharmaceuticals Ltd
Glance View
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria and currently employs 158 full-time employees. The company went IPO on 2017-11-15. In MTR therapy, radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The firm's lead products include TLX250/TLX250-CDx for diagnosis and treatment of renal (kidney) cancer; TLX591/TLX591-CDx for diagnosis and treatment of metastatic castrate-resistant prostate cancer and TLX101 for the treatment of glioblastoma (brain cancer).The Company's pipeline include development and commercialization of several clinical-stage products that address unmet medical needs in oncology and rare diseases.
See Also
What is Telix Pharmaceuticals Ltd's PP&E Net?
PP&E Net
30.5m
AUD
Based on the financial report for Dec 31, 2023, Telix Pharmaceuticals Ltd's PP&E Net amounts to 30.5m AUD.
What is Telix Pharmaceuticals Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
167%
Over the last year, the PP&E Net growth was 62%. The average annual PP&E Net growth rates for Telix Pharmaceuticals Ltd have been 85% over the past three years , 167% over the past five years .
You don't have any saved screeners yet
